{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:14:22Z","timestamp":1758759262739,"version":"3.44.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01509-9","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:57:38Z","timestamp":1754913458000},"page":"2947-2966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE\u00a0BRIGHT, a Multicentre, Open-Label, Phase\u00a03 Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Yukari","family":"Okubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Tilt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Deherder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuho","family":"Matano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"9","key":"1509_CR1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","volume":"15","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907\u201319.","journal-title":"Expert Rev Clin Immunol"},{"key":"1509_CR2","first-page":"59","volume":"11","author":"Y Lo","year":"2021","unstructured":"Lo Y, Tsai TF. Updates on the treatment of erythrodermic psoriasis. Psoriasis (Auckl). 2021;11:59\u201373.","journal-title":"Psoriasis (Auckl)"},{"issue":"Suppl 1","key":"1509_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00655-y","volume":"23","author":"S Marrakchi","year":"2022","unstructured":"Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):13\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"1509_CR4","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"H Fujita","year":"2018","unstructured":"Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235\u201370.","journal-title":"J Dermatol"},{"key":"1509_CR5","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2147\/CCID.S374556","volume":"15","author":"W Chen","year":"2022","unstructured":"Chen W, Peng C, Zheng J, et al. Bullous pemphigoid associated with erythrodermic psoriasis: a case report. Clin Cosmet Investig Dermatol. 2022;15:1805\u20138.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"1509_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1):e006450.","journal-title":"BMJ Open"},{"key":"1509_CR7","first-page":"93","volume":"6","author":"RK Singh","year":"2016","unstructured":"Singh RK, Lee KM, Ucmak D, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93\u2013104.","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"1509_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40265-020-01283-2","volume":"80","author":"S Shao","year":"2020","unstructured":"Shao S, Wang G, Maverakis E, Gudjonsson JE. Targeted treatment for erythrodermic psoriasis: rationale and recent advances. Drugs. 2020;80(6):525\u201334.","journal-title":"Drugs"},{"key":"1509_CR9","doi-asserted-by":"publisher","first-page":"2503378","DOI":"10.1155\/2021\/2503378","volume":"2021","author":"R Kolliker Frers","year":"2021","unstructured":"Kolliker Frers R, Otero-Losada M, Kobiec T, et al. Interleukin-1 links autoimmune and autoinflammatory pathophysiology in mixed-pattern psoriasis. Mediators Inflamm. 2021;2021:2503378.","journal-title":"Mediators Inflamm"},{"issue":"6","key":"1509_CR10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445\u201386.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1509_CR11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/exd.13699","volume":"27","author":"A Boehner","year":"2018","unstructured":"Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis\u2014a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27(10):1067\u201377.","journal-title":"Exp Dermatol"},{"issue":"12","key":"1509_CR12","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3390\/biomedicines9121746","volume":"9","author":"G Genovese","year":"2021","unstructured":"Genovese G, Moltrasio C, Cassano N, et al. Pustular psoriasis: from pathophysiology to treatment. Biomedicines. 2021;9(12):1746.","journal-title":"Biomedicines"},{"issue":"3","key":"1509_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","volume":"21","author":"A Raharja","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170\u20133.","journal-title":"Clin Med (Lond)"},{"issue":"10","key":"1509_CR14","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00403-014-1488-0","volume":"306","author":"M Kakeda","year":"2014","unstructured":"Kakeda M, Schlapbach C, Danelon G, et al. Innate immune cells express IL-17A\/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. Arch Dermatol Res. 2014;306(10):933\u20138.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"1509_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","volume":"140","author":"A Johnston","year":"2017","unstructured":"Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109\u201320.","journal-title":"J Allergy Clin Immunol"},{"key":"1509_CR16","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894.","journal-title":"Front Immunol"},{"issue":"10273","key":"1509_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase\u00a03 trial. Lancet. 2021;397(10273):475\u201386.","journal-title":"Lancet"},{"issue":"10273","key":"1509_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase\u00a03 trial. Lancet. 2021;397(10273):487\u201398.","journal-title":"Lancet"},{"issue":"2","key":"1509_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"2","key":"1509_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341.","journal-title":"N Engl J Med"},{"issue":"6","key":"1509_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/bjd\/ljad035","volume":"188","author":"B Strober","year":"2023","unstructured":"Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3\u00a0years in patients with moderate-to-severe plaque psoriasis: results from the BE\u00a0BRIGHT open-label extension trial. Br J Dermatol. 2023;188(6):749\u201359.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1509_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/bjd\/ljad429","volume":"190","author":"KB Gordon","year":"2024","unstructured":"Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3\u00a0years of treatment in randomized phase\u00a0III trials. Br J Dermatol. 2024;190(4):477\u201385.","journal-title":"Br J Dermatol"},{"key":"1509_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.04.038","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Langley RG, Lebwohl M, et al. Bimekizumab durability of efficacy through 196\u00a0weeks and safety through 4\u00a0years in patients with moderate to severe plaque psoriasis: results from the BE\u00a0BRIGHT open-label extension trial. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.04.038.","journal-title":"J Am Acad Dermatol"},{"key":"1509_CR24","unstructured":"Bimzelx [Package Insert; in Japanese]. Tokyo, Japan: UCB Japan Co., Ltd. 2025."},{"issue":"3","key":"1509_CR25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s13555-022-00883-y","volume":"13","author":"A Asahina","year":"2023","unstructured":"Asahina A, Okubo Y, Morita A, et al. Bimekizumab efficacy and safety in Japanese patients with plaque psoriasis in BE VIVID: a phase\u00a03, ustekinumab and placebo-controlled study. Dermatol Ther (Heidelb). 2023;13(3):751\u201368.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1509_CR26","first-page":"1952","volume":"34","author":"V Garc\u00eda-Rodr\u00edguez","year":"2024","unstructured":"Garc\u00eda-Rodr\u00edguez V, Salleras-Redonnet M. Plaque psoriasis, generalized pustular psoriasis, palmoplantar pustulosis, and acrodermatitis continua of Hallopeau successfully treated with bimekizumab: a promising therapeutic approach. Eur J Dermatol. 2024;34(4):1952\u20134013.","journal-title":"Eur J Dermatol"},{"issue":"10","key":"1509_CR27","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1111\/1346-8138.16866","volume":"50","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Kanda N. Two cases of generalized pustular psoriasis successfully treated with bimekizumab. J Dermatol. 2023;50(10):e357\u20138.","journal-title":"J Dermatol"},{"issue":"3","key":"1509_CR28","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jocd.15543","volume":"22","author":"M Megna","year":"2023","unstructured":"Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with bimekizumab. J Cosmet Dermatol. 2023;22(3):1146\u20138.","journal-title":"J Cosmet Dermatol"},{"issue":"12","key":"1509_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15952","volume":"35","author":"M Valenti","year":"2022","unstructured":"Valenti M, Gargiulo L, Ibba L, et al. Sub-erythrodermic psoriasis successfully treated with bimekizumab: a case report. Dermatol Ther. 2022;35(12):e15952.","journal-title":"Dermatol Ther"},{"key":"1509_CR30","unstructured":"Reilly Associates. WPAI:SHP V2.0. 2010. http:\/\/www.reillyassociates.net\/WPAI_SHP.html. Accessed 22 May\u00a02025."},{"issue":"5","key":"1509_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"1509_CR32","unstructured":"IQVIA. Treatment Satisfaction Questionnaire for Medication (TSQM): getting to the heart of patient treatment satisfaction. 2007. https:\/\/www.iqvia.com\/solutions\/research-and-development\/consulting\/patient-centered-endpoints\/clinical-outcome-assessments-coa\/tsqm. Accessed 22 May\u00a02025."},{"key":"1509_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson MJ, et al. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.","journal-title":"Health Qual Life Outcomes"},{"key":"1509_CR34","first-page":"2211","volume":"125","author":"T Terui","year":"2015","unstructured":"Terui T, Akiyama M, Ikeda S, et al. Practice guidelines 2014 for generalized pustular psoriasis (GPP) [in Japanese]. Jpn J Dermatol. 2015;125:2211\u201357.","journal-title":"Jpn J Dermatol"},{"issue":"2","key":"1509_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/jdv.19530","volume":"38","author":"SE Choon","year":"2024","unstructured":"Choon SE, De La Cruz C, Wolf P, et al. Health-related quality of life in patients with generalized pustular psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2024;38(2):265\u201380.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"19","key":"1509_CR36","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.3390\/jcm11195553","volume":"11","author":"K Jaworecka","year":"2022","unstructured":"Jaworecka K, Rzepko M, Marek-Jozefowicz L, et al. The impact of pruritus on the quality of life and sleep disturbances in patients suffering from different clinical variants of psoriasis. J Clin Med. 2022;11(19):5553.","journal-title":"J Clin Med"},{"issue":"7","key":"1509_CR37","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","volume":"158","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase\u00a02 and phase\u00a03 randomized clinical trials. JAMA Dermatol. 2022;158(7):735\u201344.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1509_CR38","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","volume":"89","author":"B Strober","year":"2023","unstructured":"Strober B, Paul C, Blauvelt A, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase\u00a03b trial. J Am Acad Dermatol. 2023;89(3):486\u201395.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1509_CR39","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.42282","volume":"74","author":"X Baraliakos","year":"2022","unstructured":"Baraliakos X, Deodhar A, Dougados M, et al. Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: three-year results from a phase\u00a0IIb randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022;74(12):1943\u201358.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1509_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/bjd\/ljac021","volume":"188","author":"D Thaci","year":"2023","unstructured":"Thaci D, Vender R, de Rie MA, et al. Safety and efficacy of bimekizumab through 2\u00a0years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE\u00a0BRIGHT trial. Br J Dermatol. 2023;188(1):22\u201331.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1509_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jdv.15287","volume":"33","author":"Y Okubo","year":"2019","unstructured":"Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase\u00a03 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2019;33(2):325\u201332.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1509_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/1346-8138.16667","volume":"50","author":"K Yamanaka","year":"2023","unstructured":"Yamanaka K, Okubo Y, Yasuda I, et al. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: primary analysis and 180-week follow-up results from the phase\u00a03, multicenter IMMspire study. J Dermatol. 2023;50(2):195\u2013202.","journal-title":"J Dermatol"},{"issue":"12","key":"1509_CR43","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/art.42280","volume":"74","author":"LC Coates","year":"2022","unstructured":"Coates LC, McInnes IB, Merola JF, et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: three-year results from a phase\u00a0IIb randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022;74(12):1959\u201370.","journal-title":"Arthritis Rheumatol"},{"key":"1509_CR44","unstructured":"Tremfya [Package Insert]. Horsham, Pennsylvania: Janssen Biotech; 2023."},{"key":"1509_CR45","unstructured":"Taltz [Package Insert]. Indianapolis, Indiana: Eli Lilly and Company; 2024."},{"key":"1509_CR46","unstructured":"Stelara [Package Insert]. Horsham, Pennsylvania: Janssen Biotech; 2022."},{"key":"1509_CR47","unstructured":"Bimzelx [Package Insert]. Smyrna, Georgia: UCB, Inc.; 2023."},{"issue":"5","key":"1509_CR48","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/1346-8138.14294","volume":"45","author":"S Sano","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase\u00a03, multicenter, open-label study. J Dermatol. 2018;45(5):529\u201339.","journal-title":"J Dermatol"},{"issue":"4","key":"1509_CR49","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/1346-8138.13622","volume":"44","author":"H Saeki","year":"2017","unstructured":"Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase\u00a03 study (UNCOVER-J). J Dermatol. 2017;44(4):355\u201362.","journal-title":"J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01509-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01509-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01509-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:24:24Z","timestamp":1758720264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01509-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01509-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yukari Okubo: Received research funding from AbbVie, Eisai, Maruho, Shiseido, Sun Pharma, and Torii Pharmaceutical; honoraria as a speaker, consultant, and advisory board member from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen,\u00a0Kyowa Kirin, LEO Pharma, Eli Lilly, Maruho, Novartis, Pfizer, Sanofi, Sun Pharma, Taiho Pharma, and UCB; and honoraria as a speaker from Eisai, Jimro, Mitsubishi Tanabe Pharma, and Torii Pharmaceutical. Yayoi Tada: Research grants from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Jimro, Kaken Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Meiji Seika Pharma, Sun Pharma, Taiho Pharma, Mitsubishi Tanabe Pharma, Torii Pharmaceutical, and UCB; honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Eisai, Janssen Pharma, Jimro, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Sun Pharma, Taiho Pharma, Mitsubishi Tanabe Pharma, Torii Pharmaceutical, and UCB. Hidetoshi Takahashi: Served as paid speaker sponsored by AbbVie, Amgen, Eli Lilly, Janssen, Kaken Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Sanofi, Sato Pharmaceutical, Sun Pharma, Taiho Pharma, Torii Pharmaceutical, and UCB. Masatoshi Abe: Served as paid speaker sponsored by AbbVie, Amgen, Eli Lilly, Kyowa Kirin, Maruho, Novartis, Sanofi, Torii Pharmaceutical, and UCB. Keiichi Yamanaka: Grants from Kaken Pharmaceutical, Maruho, Nihon Pharmaceutical, Nippon Kayaku, Otshuka Pharmaceutical, Sasaki Chemical, Sun Pharma, and Torii Pharmaceutical; speaker for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Eisai, Eli Lilly, Janssen, Kaken Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Nippon Kayaku, Nobelpharma, Novartis, Otshuka Pharmaceutical, Pfizer, Sanofi, Sun Pharma, Taiho Pharma, Torii Pharmaceutical, and UCB. Nicola Tilt, Nancy Cross, Delphine Deherder: Employees and shareholders of UCB. Mizuho Matano: Employee of UCB. Hidemi Nakagawa: Consulting fees and\/or speaker\u2019s fees from Japan Tobacco Inc., Maruho, Otsuka Pharmaceutical, Torii Pharmaceutical, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study protocol was reviewed by a central institutional review board (IRB, approval number MOD01178825) and the IRB of each institution prior to implementation. Written informed consent was obtained from all patients. The study was carried out in accordance with the applicable regulatory and International Council for Harmonisation-Good Clinical Practice requirements, and the Helsinki Declaration of 1964, and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}